image credit: Unsplash

Catalent antes up $230M to expand Maryland viral vector manufacturing operation

October 26, 2021

Catalent will shell out $230 million to expand the viral vector manufacturing operation at its Harmans, Maryland, gene therapy campus.

The latest project by the New Jersey-based CDMO will add three more commercial-scale viral vector suites as well as expanded storage space, ultralow temperature freezers and water-for-injection infrastructure, the company said Tuesday.

The latest investment by Catalent comes a year after the company piled $130 million into the site in the race to manufacture COVID vaccines.

Read More on FiercePharma